The earnings call highlights significant restructuring efforts and growth in the Biologics Safety Testing segment. However, these positives are countered by substantial revenue declines, increased net losses, and challenges in the U.S. market. While there are promising strategic initiatives and growth prospects in China, the financial challenges and restructuring costs present notable concerns.

Company Guidance -

Q3 2025

During the Maravai LifeSciences Second Quarter 2025 Earnings Call, CEO Bernd Brust outlined a comprehensive three-part plan aimed at realigning the company for sustainable growth. The plan includes a restructuring initiative expected to reduce annualized expenses by over $50 million through headcount and non-headcount reductions, with most savings to be realized within the next two quarters. Revenue for Q2 2025 was $47.4 million, marking a decrease from $69.4 million in Q2 2024, with the Nucleic Acid Production segment generating $31.1 million and the Biologics Safety Testing segment $16.3 million. The company reported a GAAP net loss of $69.8 million for the quarter, compared to a net loss of $18.4 million in the previous year. Adjusted EBITDA was negative $10.4 million, down from a positive $13 million in Q2 2024. Maravai ended the quarter with $270 million in cash and $297 million in long-term debt, and the new leadership team, including CFO Raj Asarpota, is focused on restoring positive adjusted EBITDA and free cash flow by the second half of 2026.

Restructuring and Cost Reduction Plan

Maravai initiated a restructuring plan to reduce operating costs by more than $50 million annually. This plan involves reducing headcount and non-headcount related expenses, with the majority of savings expected in the next two quarters.

Biologics Safety Testing Segment Growth

The Biologics Safety Testing segment reported a 10% year-over-year revenue increase, driven by demand for Host Cell Protein kits, MockV viral clearance products, and qualification services.

New Strategic Initiatives

Maravai is focused on strategic levers for long-term value creation, including revenue diversification, investment in new analytical products, and expanding GMP consumables capabilities for future mRNA applications.

Positive Prospects in China

With the easing tensions between the U.S. and China, Maravai anticipates growth opportunities in the Chinese market.

Maravai Lifesciences Holdings (MRVI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MRVI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.08 / -	-0.02	―	―	―
Aug 11, 2025	2025 (Q2)	-0.07 / -0.08	0	―
May 12, 2025	2025 (Q1)	-0.07 / -0.08	-0.02	-300.00% (-0.06)
Mar 18, 2025	2024 (Q4)	-0.04 / -0.06	0.01	-700.00% (-0.07)
Nov 07, 2024	2024 (Q3)	>-0.01 / -0.02	-0.01	-100.00% (-0.01)
Aug 07, 2024	2024 (Q2)	<0.01 / 0.00	0	―
May 08, 2024	2024 (Q1)	-0.03 / -0.02	0.03	-166.67% (-0.05)
Feb 22, 2024	2023 (Q4)	-0.01 / 0.01	0.35	-97.14% (-0.34)
Nov 07, 2023	2023 (Q3)	<0.01 / -0.01	0.37	-102.70% (-0.38)
Aug 07, 2023	2023 (Q2)	0.01 / 0.00	0.54	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MRVI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$2.06	$2.69	+30.58%
May 12, 2025	$2.12	$2.06	-2.83%
Mar 18, 2025	$2.58	$2.43	-5.81%
Nov 07, 2024	$7.84	$5.08	-35.20%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Maravai Lifesciences Holdings, Inc. (MRVI) report earnings?

Maravai Lifesciences Holdings, Inc. (MRVI) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Maravai Lifesciences Holdings, Inc. (MRVI) earnings time?

Maravai Lifesciences Holdings, Inc. (MRVI) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MRVI EPS forecast?

MRVI EPS forecast for the fiscal quarter 2025 (Q3) is -0.08.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing